Hints and tips:
Related Special Reports
...Novo Nordisk is exploring ways to spread the cost of the drugs over several years so health systems can better capture the potential cost savings from preventing expensive events such as heart attacks....
...Novo Nordisk is in talks with healthcare systems about innovative pricing deals for its Wegovy weight loss drug, as it hopes to expand take-up of the obesity treatment by helping health services spread the...
...To help convince healthcare providers and to increase take-up, Novo Nordisk is in talks with healthcare systems about contracts that allow them to spread the costs of Wegovy over many years....
...Ozempic” takes, referring to the diabetes and obesity medicine produced by Eli Lilly’s rival in the category, Novo Nordisk....
...ease pressure on health insurance and care systems....
...Developing drugs that can also tackle illnesses associated with obesity is key to convincing more health systems to pay for them....
...To try to reach more patients, Novo Nordisk is in talks with health systems about flexible pricing to allow them to defer some of the cost of the drugs until they are seeing benefits....
...The US Food and Drug Administration says there is a shortage of Novo Nordisk’s and Eli Lilly’s diabetes drugs, while Belgium has banned the off-label use of Novo Nordisk’s diabetes drug for obesity treatments...
...Novo Nordisk’s weight-loss drug Wegovy cut the risk of death by 18 per cent in a trial that the Danish pharmaceutical company hopes will convince more health systems and insurers to pay for the treatment...
...Novo Nordisk’s blockbuster offering Wegovy is expected to be approved for sale in China this year. That would be another boost for the Danish company....
...Another difference is that the foundation can share its findings with health systems more widely because, unlike a company, it has no need to protect proprietary data....
...The trial is part of Novo Nordisk’s plan to invest in collecting more evidence to show healthcare systems that the drugs have a significant impact on people’s long-term health and prove they are worth paying...
...Not only are other pharma groups scrambling to buy up biotechs with promising obesity drugs, but Eli Lilly and Novo Nordisk also are putting the drugs to work on other disease areas....
...The wider health benefits of a new class of diabetes and weight loss drugs are considered key to convincing health systems to pay for the treatments, and have led analysts to forecast that the value of the...
...The results led analysts to predict that Novo would be able to persuade more insurers and health systems to pay for the drug....
...Novo Nordisk’s obesity drug cuts the risk of major cardiovascular events such as heart attacks or strokes by 20 per cent compared with a placebo, bolstering the Danish drugmaker’s case that health systems...
...Investors hope the data will prove to health systems and insurers that the medicine, which has made headlines as a rich person’s slimming tool, could actually save lives and costs....
...The same dog-avoidance benefit probably contributed to actives beating passives last year in Denmark, where selling Ørsted and Genmab on the first sniff of trouble while holding on to Novo Nordisk would...
...So it’d be really interesting to see whether that changes the game for some health systems. Michela Tindera Mmm....
...Novo Nordisk and Eli Lilly have struggled to keep up with soaring demand for obesity treatments....
...Two years later, the entire banking system was on the brink of collapse and billions of taxpayer dollars were used to prop it back up....
...Analysts believe the trial — the largest conducted by the company — will help Novo persuade more health systems and insurers to pay for the drug....
...The UK is presented as a sad counterpoint, “paralysed by a financial system of absent owners”, deprived of the regional relationship-banking system that shores up German capitalism and bereft of the business...
...But both health systems and insurers, including the NHS, negotiate confidential discounts....
...Still, Delaware, Inc is going to have to decide whether its brand should be based on being an even-handed, dispassionate system or something more corporate-friendly, designed to keep up in a regulatory race...
International Edition